Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (SNYNF)
OTHER OTC:SNYNF
Holding SNYNF?
Track your performance easily
SNYNF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$90.15 - $121.06
Previous CloseN/A
Volume2.00
Average Volume (3M)27.52K
Market Cap
$132.02B
Enterprise ValueN/A
Total Cash (Recent Filing)$10.30B
Total Debt (Recent Filing)$16.82B
Price to Earnings (P/E)28.9
Beta0.32
Next Earnings
Jan 30, 2025EPS Estimate
1.48Last Dividend Ex-Date
May 13, 2024Dividend Yield3.86%
Share Statistics
EPS (TTM)3.65
Shares Outstanding1,263,122,700
10 Day Avg. Volume55,724
30 Day Avg. Volume27,516
Standard Deviation0.06
R-Squared0.08
Alpha0.00039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$116.91Price Target Upside10.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Sanofi News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessSanofi/Teva released headline data from PIIb RELIEVE-UCCD which showed duvakitug (anti-TL1A) hit primary endpoints in ulcerative colitis (UC) and Crohn’s disease (CD), suggesting best-in-class asset potential.
Growth ProspectsSAN FP is poised for strong growth over the next five years, with no major patent expirations expected during this period.
Pipeline And ResearchSanofi's improving pipeline, with significant upcoming data sets and multiple Phase II reads in immunology and inflammation, is likely to boost research and development sentiment.
Bears Say
Competitive PositionSanofi is 1-2 years behind Merck and 6 months to 1 year behind Roche/Roivant in the development of treatments for UC and CD.
Earnings PerformanceAn EPS reset is needed before Sanofi can outperform, suggesting some current underperformance.
Stock VolatilityThere could be stock volatility when SAN reports results on January 30.
---
Ownership Overview
―
Insiders
13.12% Mutual Funds
<0.01% Other Institutional Investors
72.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
SNYNF FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was $90.15 and its highest was $121.06 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $132.02B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Jan 30, 2025 which is today.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Oct 25, 2024. The company reported $2.975 earnings per share for the quarter, beating the consensus estimate of $2.582 by $0.393.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of $3.868 which represents an annual dividend yield of 3.86%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.48.
How many shares outstanding does Sanofi have?
Sanofi has 1,263,122,700 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $2.975 in its last earnings report, beating expectations of $2.582. Following the earnings report the stock price went up 4.973%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in SNYNF
---
Company Description
Sanofi
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
---
SNYNF Company Deck
---
SNYNF Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong sales performance, driven by key products like Dupixent and successful pharma launches, leading to raised EPS guidance. However, challenges such as product exclusivity losses and regulatory impacts were noted. Overall, the positive aspects significantly outweigh the challenges.Read More>---
SNYNF Stock 12 Month Forecast
Average Price Target
$116.91
▲(10.45% Upside)
Technical Analysis
Best Analysts Covering SNYNF
1 Year
1 Year Success Rate
17/22 ratings generated profit
1 Year Average Return
+4.68%
reiterated a buy rating 10 days ago
Copying Graham Parry's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +4.68% per trade.
---